NHS Providers | February 2019 | On the day briefing: A five year framework for GP contract reform to implement the NHS long term plan
NHS Providers and the British Medical Association’s (BMA) GP committee have reached an agreement for general practice contract reform for the next five years with the aim of supporting the delivery of the NHS Long term plan.
This briefing summarises the changes set out in the contract, and explores the potential implications for trusts and their local partnerships with primary care.
Read the briefing: A five year framework for GP contract reform to implement the NHS long term plan
Investment and evolution: A five year framework for GP contract reform to implement The NHS Long Term Plan
Department of Health and Social Care | February 2019 | Learning disability and autism training for health and care staff
The government wants to know how they can make sure that health and social care staff have the right training to understand the needs of people with a learning disability and autistic people, and make reasonable adjustments to support them.
The consultation considers issues around the training and development staff need to better support people with a learning disability or autistic people.
The Department of Health and Social Care want to know what people think about our proposals on:
- the planned content of the training
- how the training should be delivered
- how to involve people with a learning disability or autistic people in training
- how we can mandate, monitor and evaluate the impact of training
The consultation will be of particular interest to:
- people with a learning disability or autistic people
- the families and carers of people with a learning disability or autistic people
- patient groups
- providers of health and social care services (Source: Department of Health and Social Care)
Learning disability and autism training for health and care staff: consultation document
Learning disability and autism training for health and care staff: easy read version
Full details of how to respond are available from Department of Health and Social Care
Specialist Pharmacy Services | February 2019 | The Future of Aseptic Pharmacy Services in England: Report on Phase 1 of the NHSI Review (Feb 2019)
NHS Improvement undertook a review of the provision pharmacy aseptic services including MHRA licensed, unlicensed an outsourced (both from NHS Providers and non-NHS commercial suppliers) activity. Product categories included in the review are chemotherapy, parenteral nutrition, clinical trials / investigational medicinal products, and pharmacy-led radiopharmacy.
Specific aspects of these services on which information was sought included: geographical location, capacity (staff and facilities), estate & equipment, management structure, staffing establishment, operational costs, service hours, range of products & services provided, and customer base.
This report summarises findings from the first phase of the Review and recommended next steps to be taken in Phase 2, which started in February 2019 (Source: Specialist Pharmacy Services
PowerPoint The Future of Pharmacy Aseptic Services in England Feb 19
NHS England | n.d | Staff wellbeing is everyone’s responsibility at Islington iCope
A case study from NHS England highlights how a team at Islington iCope considered and introduced measures to support their own wellbeing. To help patients improve their mental health, NHS staff also need to take care of their own wellbeing. A team of Psychological Wellbeing Practitioners (PWPs) at Islington iCope therapies service was keen to think about how they could support their own wellbeing among the pressures and challenges of delivering Improving Access to Psychological Therapies (IAPT) services. Starting with a Wellbeing Action Day, the PWP team worked with managers to bring about a number of meaningful changes (Source: NHS England).
Staff wellbeing is everyone’s responsibility at Islington iCope
NIHR | February 2019 | Treatments for depression may help irritable bowel symptoms
A systematic review that looked at the the effects of antidepressants versus placebo in 17 trials and psychological therapies versus a control therapy or usual care (symptom monitoring, physician’s usual management, or supportive therapy) in 35 trials. All of the trials were conducted in middle-income countries, with four of the trials from the UK.
Antidepressants are likely to provide more than a placebo effect for those with symptoms of irritable bowel syndrome (IBS). Antidepressants improve symptoms in about 60% of those taking them, but two-thirds of that effect may be due to placebo. Psychological therapies, such as talking therapies also appear effective in about half of those offered them but may be partly due to expectations because it is not possible to provide a placebo control.
IBS is a chronic disorder of the gut which commonly causes pain, bloating, stomach cramps and diarrhoea or constipation. Despite these symptoms, no structural abnormality is present, so it is described as a functional disorder. People with these symptoms often have coexisting anxiety or depression, and there is a theory that the syndrome, a collection of symptoms, may be due to a disorder of brain-gut function.
This systematic review identified 53 randomised controlled trials. The review concluded that antidepressants are effective in reducing symptoms of irritable bowel syndrome, as the symptoms improved for more people taking antidepressants than those taking a placebo. There is also evidence to suggest that psychological therapies also appear to be effective treatments, particularly where a therapist is directly involved (Source: NIHR).
Read the full Signal at NIHR